Semaglutide for metabolic dysfunction-associated steatohepatitis (MASH): Estimating eligibility from the 2021-2023 National Health and Nutrition Examination Survey (NHANES).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Endocrine meets hepatic: the thyroid-liver axis in health and disease-an overview.Wiener medizinische Wochenschrift (1946) · 2026
   Review
2. Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut and liver · 2026
   Review
3. Complex I Modulator BI4500 Reduces MASH by Limiting Oxidative Stress and Reprogramming Lipid Metabolism via AMPK in MCD Rats.Antioxidants (Basel, Switzerland) · 2026
   Article
4. Dapagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential.Euroasian journal of hepato-gastroenterology
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as